Iga Nephropathy- Oral Medication
Posted Date: Oct 29, 2021
- Investigator: Manish Anand
- Specialties:
- Type of Study: Drug
IgA nephropathy (IgAN) is a kidney disease that occurs when an antibody known as immunoglobulin A builds up in the kidneys and causes inflammation and scarring within the kidney. It is most often diagnosed with a kidney biopsy. For many people with IgAN, this damage to the kidneys can worsen over time, and can result in severe kidney disease and/or high levels of protein in the urine (proteinuria). Currently there are no proven treatments for IgAN. This study will evaluate the safety and effectiveness of a new oral medication, called LNP023, which is an investigational drug, and has not yet been approved by the FDA. The study is placebo controlled, meaning that half of the participants will randomly be assigned to receive LNP023, and half will be randomly assigned to receive placebo The study will last for at least 2 years, with study visits every 1-3 months.. Side effects from the medication may include susceptibility to infections, so you may receive vaccinations for the most common ones. Subjects are compensated for time in the study.
Criteria:
Proven Iga Nephropathy Diagnosed By Biopsy Within Last 5 Years. Current Egfr (Measure Of Kidney Function) Greater Than 30 Ml/Min, And High Level Of Protein In The Urine (Upcr >1G/G,. Subjects Must Have Stable Blood Pressure And Blood Pressure Medications. Subjects Cannot: Be In Any Other Investigational Drug Studies, Have Rapid Progression Of Kidney Disease, Or Have Severe Cardiac Or Liver Disease, Or Any Active Infections. Women Who Are Able To Become Pregnant Must Not, And Must Agree To Use Birth Control During The Study. All Subjects Must Be Able To Attend The Study Visits, Some Within The Ucmc Sites And Some At A Research Clinic.
Keywords:
Renal, Kidney, Proteinuria
For More Information:
Heather Duncan
513-559-3362
heather.duncan@uc.edu